Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
Cefpiramide sodium is a third-generation cephalosporin antibiotic administered by injection for the treatment of bacterial infections. It functions as a beta-lactam antibiotic that inhibits bacterial cell wall synthesis. The drug has been in the market since 1989 and is positioned as a broad-spectrum injectable option for moderate-to-severe infections.
With LOE approaching and no linked jobs currently, this product faces diminishing commercial opportunity and likely offers only defensive, maintenance-focused roles.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on cefpiramide sodium in the LOE phase offers limited career growth and primarily defensive responsibilities focused on maintaining market share against generics and managing formulary relationships. This role is best suited for professionals seeking experience in product lifecycle management, mature market operations, or generic transition planning rather than commercial expansion or innovation.
Worked on CEFPIRAMIDE SODIUM at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.